Natera (NASDAQ:NTRA) CEO Sells $19,680,185.28 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 85,299 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $230.72, for a total value of $19,680,185.28. Following the completion of the sale, the chief executive officer owned 127,881 shares in the company, valued at approximately $29,504,704.32. This represents a 40.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, February 3rd, Steven Leonard Chapman sold 4,725 shares of Natera stock. The shares were sold at an average price of $230.77, for a total value of $1,090,388.25.
• On Wednesday, January 28th, Steven Leonard Chapman sold 3,648 shares of Natera stock. The shares were sold at an average price of $237.66, for a total transaction of $866,983.68.
• On Tuesday, January 27th, Steven Leonard Chapman sold 2,322 shares of Natera stock. The stock was sold at an average price of $240.53, for a total transaction of $558,510.66.
• On Wednesday, January 21st, Steven Leonard Chapman sold 1,590 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $373,650.00.
• On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The shares were sold at an average price of $234.74, for a total value of $16,885,317.68.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The shares were sold at an average price of $229.08, for a total value of $881,499.84.
• On Monday, December 1st, Steven Leonard Chapman sold 4,400 shares of Natera stock. The stock was sold at an average price of $238.07, for a total value of $1,047,508.00.

Natera Trading Up 3.0%

NASDAQ:NTRA opened at $203.04 on Friday. The company has a 50-day moving average of $233.31 and a 200-day moving average of $196.18. The firm has a market cap of $28.08 billion, a price-to-earnings ratio of -88.66 and a beta of 1.64. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36.

Natera (NASDAQ:NTRA) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The company’s quarterly revenue was up 34.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.26) earnings per share. On average, research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in NTRA. Flagship Harbor Advisors LLC bought a new position in Natera during the fourth quarter valued at approximately $41,000. Hilltop National Bank bought a new position in shares of Natera during the 2nd quarter valued at $33,000. Horizon Investments LLC bought a new stake in Natera in the third quarter worth $32,000. Sound Income Strategies LLC increased its position in Natera by 95.7% during the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after buying an additional 110 shares during the last quarter. Finally, TD Waterhouse Canada Inc. bought a new position in Natera during the fourth quarter valued at about $62,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Stephens upped their price target on shares of Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Guggenheim lifted their price objective on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Canaccord Genuity Group reaffirmed a “buy” rating on shares of Natera in a research report on Monday, January 12th. Finally, Citigroup started coverage on Natera in a research report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average price target of $249.20.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.